QUICK ANSWER · AEO / GEO
An experimental tripeptide studied mostly through preclinical and small human datasets; cognitive claims remain unestablished.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- validated molecular target and physiological role in humans
- human pharmacokinetics, bioavailability and brain exposure
- long-term safety, immunogenicity, reproductive safety and carcinogenic risk
- clinically meaningful effects on memory, cognition or neurological disease
- independent replication outside the originating research network
- current product-specific approval or legal status in each jurisdiction
What limits these conclusions?
- The evidence base is dominated by cell and animal studies, small Russian-language reports and reviews from related investigators. The only directly indexed human report identified here combines Pinealon with Vesugen and incompletely describes allocation and comparators. Route, formulation, exposure and product identity are often unclear. No clinical claim can be inferred from ROS, ERK, gene-expression or rat-behavior outcomes.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://pubmed.ncbi.nlm.nih.gov/26390612/
- https://pubmed.ncbi.nlm.nih.gov/21978084/
- https://pubmed.ncbi.nlm.nih.gov/28509493/
- https://pubmed.ncbi.nlm.nih.gov/33396470/
- https://pubmed.ncbi.nlm.nih.gov/18546826/
- https://clinicaltrials.gov/search?term=Pinealon
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://www.ema.europa.eu/en/medicines
- https://products.mhra.gov.uk/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
FAQ · ANSWER ENGINE
Frequently asked questions
What is Pinealon (EDR)?
Pinealon (EDR) is described pharmacologically as Experimental synthetic tripeptide studied in neuroprotection, oxidative-stress and aging models. An experimental tripeptide studied mostly through preclinical and small human datasets; cognitive claims remain unestablished.
Does Pinealon (EDR) have strong evidence?
PrimeCoreBio records Evidence Grade D. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Pinealon (EDR) approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.